1. Home
  2. DAWN vs ESE Comparison

DAWN vs ESE Comparison

Compare DAWN & ESE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Day One Biopharmaceuticals Inc.

DAWN

Day One Biopharmaceuticals Inc.

HOLD

Current Price

$9.59

Market Cap

624.8M

Sector

Health Care

ML Signal

HOLD

Logo ESCO Technologies Inc.

ESE

ESCO Technologies Inc.

HOLD

Current Price

$201.87

Market Cap

5.5B

ML Signal

HOLD

Company Overview

Basic Information
Metric
DAWN
ESE
Founded
2018
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Telecommunications Equipment
Sector
Health Care
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
624.8M
5.5B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
DAWN
ESE
Price
$9.59
$201.87
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
2
Target Price
$26.56
$237.50
AVG Volume (30 Days)
2.9M
224.4K
Earning Date
11-04-2025
02-05-2026
Dividend Yield
N/A
0.16%
EPS Growth
N/A
193.06
EPS
N/A
11.55
Revenue
$133,672,000.00
$1,095,388,000.00
Revenue This Year
$15.51
$18.95
Revenue Next Year
$49.99
$6.83
P/E Ratio
N/A
$44.65
Revenue Growth
31.11
19.18
52 Week Low
$5.64
$127.17
52 Week High
$13.53
$229.46

Technical Indicators

Market Signals
Indicator
DAWN
ESE
Relative Strength Index (RSI) 58.46 44.63
Support Level $8.13 $196.24
Resistance Level $9.82 $208.89
Average True Range (ATR) 0.59 5.00
MACD 0.10 0.47
Stochastic Oscillator 64.40 44.46

Price Performance

Historical Comparison
DAWN
ESE

About DAWN Day One Biopharmaceuticals Inc.

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.

About ESE ESCO Technologies Inc.

ESCO Technologies Inc sells engineered products and systems for utility, industrial, aerospace, and commercial applications. The firm operates in three segments: Aerospace and Defense, Utility Solutions Group (USG), and Test. The Aerospace and Defense segment designs and manufactures specialty filtration and naval products. The USG segment provides diagnostic testing solutions. The Test segment provides its customers with the ability to identify, measure, and contain magnetic, electromagnetic, and acoustic energy.

Share on Social Networks: